克服瘤基因驱动的NSCLC中MET介导的耐药性
Nadine Reischmann1, Carolin Schmelas1, Miguel Ángel Molina-Vila2
1The Healthcare Business of Merck KGaA, Darmstadt, Germany.
iScience
|August 3, 2023
概括
在非小细胞肺癌 (NSCLC) 中,MET过度表达会导致对向治疗的耐药性. 将向疗法与MET或SHP2抑制剂结合起来,可以有效地克服各种NSCLC亚型中的这种抗性.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 针对性治疗对于非小细胞肺癌 (NSCLC) 治疗至关重要.
- 对氨酸激酶抑制剂 (TKI) 的耐药性是NSCLC的重大临床挑战.
- MET放大/过度表达是TKI抵抗的一个新兴机制.
研究的目的:
- 评估将向疗法与MET或SHP2抑制剂结合的疗效.
- 克服多种非小细胞肺癌 (NSCLC) 亚型中MET介导的耐药性.
- 评估TKI耐性NSCLC中MET放大和过度表达的患病率.
主要方法:
- 在TKI复发后的NSCLC患者样本中MET放大和过度表达的流行研究.
- 在各种突变NSCLC细胞系 (EGFR,KRAS,HER2,NTRK1) 中证实了MET介导的耐药性.
- 在体外和体内测试测试组合疗法 (向疗法+MET/SHP2抑制剂).
主要成果:
- 在37.5%的组织活检和7.4%的液体活检中检测到MET介导的耐药性.
- 证实MET过度表达是EGFR,KRAS,HER2和NTRK1突变NSCLC细胞系中抗性的驱动因素.
- 与MET或SHP2抑制剂的联合治疗成功克服了MET介导的耐药性.
结论:
- MET过度表达是用向疗法治疗NSCLC的关键抵抗机制.
- 组织活检在检测MET过度表达方面比液体活检更有效.
- 涉及MET或SHP2抑制剂的组合策略有望克服耐药性并改善NSCLC患者的治疗结果.
更多相关视频
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
7.3K
10:09Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
Published on: January 7, 2019
8.3K
相关概念视频
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Metastasis
5.6K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.6K
Mitogens and the Cell Cycle
6.6K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K
Cancer Stem Cells and Tumor Maintenance
5.0K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
5.0K
